შაბათი, მაისი 2, 2026
- Advertisement -
Google search engine
Global Ingredient Risk Index Excipient

Caramel Color

Caramel color (E150a/b/c/d)

Also known as: caramel color, caramel colouring, E150, burnt sugar

LOW RISK 3.5/10 How?

This ingredient is classified as unclassified risk (GIRI score: 3.5/10).

02

Safety Profile

Known Safety Concerns

  • Class IV (E150d) contains 4-MEI -- California Prop 65 carcinogen listing
  • Type of caramel color rarely disclosed on supplement labels
  • 4-MEI caused cancer in animal studies at high doses -- human relevance debated
  • CSPI has petitioned FDA to ban certain caramel colors

Contraindications

  • Class IV (E150d) contains 4-MEI -- California Prop 65 carcinogen listing
  • Type of caramel color rarely disclosed on supplement labels
═══════════════════════════════════════════════════════════════════════ -->
03

Interactions

Information not yet available for this ingredient profile.

═══════════════════════════════════════════════════════════════════════ -->
04

Evidence and Scientific Findings

Overview

Ingredient Overview

Caramel color is the most widely consumed food coloring globally. Class IV caramel (E150d — ammonia-sulfite process) contains 4-methylimidazole (4-MEI), which the state of California lists as a probable carcinogen (Prop 65). This class is commonly used in cola drinks and some supplement syrups. Classes I and II have better safety profiles. The type of caramel color is rarely specified on supplement labels.

Classification

Biological and Chemical Classification

Scientific Name
Caramel color (E150a/b/c/d)
Mechanism

Mechanism of Action

Information not yet available for this ingredient profile.

Clinical Evidence

Clinical Evidence of Effectiveness

Information not yet available for this ingredient profile.

Pharmacokinetics

Pharmacokinetics

Information not yet available for this ingredient profile.

Dosage

Recommended Dosage

Information not yet available for this ingredient profile.

═══════════════════════════════════════════════════════════════════════ -->
05

SETI — Scientific Evidence Transparency Index

SETI Score 50/100
Risk Level High risk
Scientific Confidence Low
Evidence Strength Limited
Key Benefit Excipient
Key Safety Concern Class IV (E150d) contains 4-MEI -- California Prop 65 carcinogen listing
Evidence Reviewed 10 PubMed studies
Scientific Confidence Low
Based on study quality, consistency, and recency

Executive Summary — Ingredient Assessment

SETI Score 50/100
Risk Level High risk
Evidence Strength Limited
Main Benefit Excipient
Main Safety Concern Class IV (E150d) contains 4-MEI -- California Prop 65 carcinogen listing
Ingredient Caramel Color
Scientific name Caramel color (E150a/b/c/d)
Scientific Evidence Overview
  • 10 studies reviewed
  • 0 high-quality studies (meta-analysis or RCT)
  • Main clinical benefit observed: Excipient
  • Evidence consistency: High consistency across studies (100%)
Safety Signals
  • Class IV (E150d) contains 4-MEI -- California Prop 65 carcinogen listing
  • Type of caramel color rarely disclosed on supplement labels
  • 4-MEI caused cancer in animal studies at high doses -- human relevance debated
  • CSPI has petitioned FDA to ban certain caramel colors
Evidence Strength Limited
Final Scientific Assessment

The available scientific evidence for Caramel Color indicates notable safety signals that warrant caution. Use should be considered carefully and monitored, particularly in sensitive populations or alongside other medications.

Ingredient Caramel Color
Evidence reviewed 10 peer-reviewed studies (last 10 years)
Scientific name Caramel color (E150a/b/c/d)
50 /100

Total SETI Score

High risk
Evidence quality 10/40
Evidence consistency 20/20
Safety signals 0/20
Study recency 10/10
Evidence transparency 10/10

Evidence Summary

  • 10 studies reviewed
  • 0 high-quality studies (meta-analysis or systematic review)
  • 0 studies identified benefits or no safety concern (GREEN)
  • 10 studies reported limited or advisory safety evidence (YELLOW)

Evidence Policy

Only peer-reviewed scientific literature indexed in PubMed or comparable databases is included in this evaluation. Commercial websites, blogs, and marketing materials are excluded. All references include direct traceable links to source documents.

Last updated: 24 მარ 2026, 09:34

Evidence Distribution

10 Other / unclassified
  1. Observational / other LOW evidence YELLOW
    Dual-functional carbon dots for fluorescent detection of L-Glutamic acid and 2-Methylimidazole in complex matrices: Applications in food safety and environmental monitoring. ↗
    Journal Anal Chim Acta
    Year 2025
    Study type Observational / other
    Evidence strength LOW evidence
    Ju Y et al.. Dual-functional carbon dots for fluorescent detection of L-Glutamic acid and 2-Methylimidazole in complex matrices: Applications in food safety and environmental monitoring.. Anal Chim Acta. 2025. PMID:41167902.
  2. Observational / other LOW evidence YELLOW
    Reproductive and developmental toxicity risk assessment for 4-methylimidazole. ↗
    Journal Regul Toxicol Pharmacol
    Year 2025
    Study type Observational / other
    Evidence strength LOW evidence
    Scialli AR. Reproductive and developmental toxicity risk assessment for 4-methylimidazole.. Regul Toxicol Pharmacol. 2025. PMID:40412543.
  3. Observational / other LOW evidence YELLOW
    Unraveling the Physicochemical, Nutritional and Antioxidant Properties of the Honey Produced from the Fallopia japonica Plant. ↗
    Journal Foods
    Year 2024
    Study type Observational / other
    Evidence strength LOW evidence
    Cucu AA et al.. Unraveling the Physicochemical, Nutritional and Antioxidant Properties of the Honey Produced from the Fallopia japonica Plant.. Foods. 2024. PMID:38998468.
  4. Observational / other LOW evidence YELLOW
    Immunotoxicity of 2-Acetyl-4-tetrahydroxybutylimidazole in BALB/c mice with different vitamin B6 nutritional statuses. ↗
    Journal Toxicology
    Year 2024
    Study type Observational / other
    Evidence strength LOW evidence
    Yuan L et al.. Immunotoxicity of 2-Acetyl-4-tetrahydroxybutylimidazole in BALB/c mice with different vitamin B6 nutritional statuses.. Toxicology. 2024. PMID:38768702.
  5. Observational / other LOW evidence YELLOW
    Level Optimization of Beet Powder and Caramel Color for Beef Color Simulation in Meat Analogs before and after Cooking. ↗
    Journal Food Sci Anim Resour
    Year 2023
    Study type Observational / other
    Evidence strength LOW evidence
    Lee S et al.. Level Optimization of Beet Powder and Caramel Color for Beef Color Simulation in Meat Analogs before and after Cooking.. Food Sci Anim Resour. 2023. PMID:37701740.
  6. Observational / other LOW evidence YELLOW
    Effects of 2-acetyl-4-tetrahydroxybutylimidazole exposure during gestation and lactation on maternity and offspring immune function in Balb/c mice. ↗
    Journal Toxicology
    Year 2023
    Study type Observational / other
    Evidence strength LOW evidence
    Zhao Z et al.. Effects of 2-acetyl-4-tetrahydroxybutylimidazole exposure during gestation and lactation on maternity and offspring immune function in Balb/c mice.. Toxicology. 2023. PMID:37531992.
  7. Observational / other LOW evidence YELLOW
    4-Methylimidazole, a carcinogenic component in food, amount, methods used for measurement; a systematic review. ↗
    Journal Food Chem X
    Year 2023
    Study type Observational / other
    Evidence strength LOW evidence
    Akbari N et al.. 4-Methylimidazole, a carcinogenic component in food, amount, methods used for measurement; a systematic review.. Food Chem X. 2023. PMID:37397204.
  8. Observational / other LOW evidence YELLOW
    Mechanisms of Rebaudioside A Degradation and Ingredient-Sweetener Interactions in Beverages during Storage. ↗
    Journal Molecules
    Year 2022
    Study type Observational / other
    Evidence strength LOW evidence
    Gelinas BS et al.. Mechanisms of Rebaudioside A Degradation and Ingredient-Sweetener Interactions in Beverages during Storage.. Molecules. 2022. PMID:35209174.
  9. Observational / other LOW evidence YELLOW
    Processing of coconut sap into sugar syrup using rotary evaporation, microwave, and open-heat evaporation techniques. ↗
    Journal J Sci Food Agric
    Year 2020
    Study type Observational / other
    Evidence strength LOW evidence
    Asghar MT et al.. Processing of coconut sap into sugar syrup using rotary evaporation, microwave, and open-heat evaporation techniques.. J Sci Food Agric. 2020. PMID:32337729.
  10. Observational / other LOW evidence YELLOW
    Multigenerational reproductive assessment of 4-methylimidazole administered in the diet to Hsd:Sprague Dawley SD rats. ↗
    Journal Reprod Toxicol
    Year 2020
    Study type Observational / other
    Evidence strength LOW evidence
    Behl M et al.. Multigenerational reproductive assessment of 4-methylimidazole administered in the diet to Hsd:Sprague Dawley SD rats.. Reprod Toxicol. 2020. PMID:32229253.
═══════════════════════════════════════════════════════════════════════ -->
06

Score Transparency

Q × L × D × S × 10 = 3.5 / 10

The GIRI Score is the product of four independently computed evidence components, each normalised to 0–1, then scaled to 0–10. Every component is derived exclusively from peer-reviewed references and regulatory data — no editorial judgement is applied.

Q
Evidence Quantity 0 / 10
0%

0 of 10 approved references (score saturates at 10). More peer-reviewed studies = stronger evidence base.

Method: Q = number of approved references ÷ 10 (capped at 1.0)

L
Evidence Quality 5 / 10
50%

Limited — mostly case reports or animal studies

Method: L = mean study-level weight across approved references. Level 1 (meta-analysis / systematic review) = 1.0; Level 2 (RCT) = 0.8; Level 3 (cohort/case-control) = 0.6; Level 4 (case report) = 0.4; Level 5 (animal / in-vitro) = 0.2.

D
Evidence Direction 5 / 10
Benefit
Risk
50%

Mixed or neutral — roughly equal benefit and risk signals

Method: D = (sum of risk-scored references − sum of benefit-scored references) ÷ total evidence score, then scaled from [−1, 1] to [0, 1]. 0.0 = pure benefit; 0.5 = neutral; 1.0 = pure risk.

S
Safety Signals 5 / 10
50%

One or more monitoring-level safety signals active

Method: S = 0.5 (neutral baseline) + sum of active signal severity deltas ÷ 10. Severity deltas: Critical = +2.0, High = +1.5, Moderate = +1.0, Low = +0.5. Capped at 1.0.

0Q × 5L × 5D × 5S = 3.5 / 10

Final GIRI Score for Caramel Color. Risk level thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.

Full methodology & data sources

The GIRI Score is computed entirely from structured data — no editorial scoring or subjective weighting is applied at any step.

  • References: Only approved references are counted. Each reference is assigned an evidence level (L1–L5) and a direction (risk / neutral / benefit) by the reference manager or AI classifier.
  • Safety Signals: Sourced from regulatory agencies (FDA, EMA, Health Canada, TGA, and others) and pharmacovigilance databases. Only active signals count toward the score.
  • Formula version: GIRI Score v3.7.0 — Q × L × D × S × 10.
  • Limitations: The score reflects published evidence and recorded signals as of the last update date. It is not a clinical risk assessment and should not replace advice from a qualified healthcare professional.
07

Risk Level Classification

LOW RISK 3.5/10

Based on available regulatory signals and scientific evidence, this ingredient presents a low safety concern under normal conditions of use.

LOW
0–3.0
MODERATE
3.0–5.5
HIGH
5.5–7.5
CRITICAL
7.5–10
3.5

The score pin shows exactly where this ingredient falls on the fixed risk scale.

What drove the Low classification for Caramel Color

GIRI Score 3.5 / 10

A score of 3.5 places this ingredient in the Low band. Thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.

Evidence Quantity (Q) 0 / 10 refs

0 approved references.

Evidence Quality (L) 50%

Limited — mostly case reports or animal studies (Level 4–5).

Evidence Direction (D) 50% toward risk

Neutral or mixed — benefit and risk signals roughly balanced.

Safety Signals (S) 0 active signals

No active signals — S component is at neutral baseline (0.5), contributing no extra risk weight.

Regulatory Status No restrictions found

No major regulatory restrictions or advisories recorded across monitored jurisdictions (FDA, EMA, Health Canada, TGA, and others).

How are the Low / Moderate / High / Critical thresholds defined?

The four risk levels are fixed score bands. A score is assigned to exactly one level based on where it falls:

LevelScoreMeaning
LOW0.0 – 2.9Sparse or predominantly beneficial evidence. No active safety alerts.
MODERATE3.0 – 5.4Mixed signals — some risk alongside benefit. Caution at high doses or in sensitive groups.
HIGH5.5 – 7.4Multiple studies or regulatory alerts documenting adverse effects. Professional oversight recommended.
CRITICAL7.5 – 10Regulatory restrictions in one or more major jurisdictions. Serious documented harm. Avoid without specialist supervision.

Thresholds are fixed constants (GIRI_Score_Utils::LEVEL_THRESHOLDS). They do not change per ingredient and are never subject to editorial adjustment.

შენიექიმი
sheniekimi.ge · PHIG
გამარჯობა 👋
სასურველი სერვისი აირჩიეთ ქვემოთ
⚡ გადაუდებელი შემთხვევა?
მყისიერი სამედიცინო დახმარება
📞 112
🩺
სიმპტომების შეფასება
150 კლინიკური სცენარი · WHO · AHA · NICE · 29 CDR
💉
ვაქცინაციის კალენდარი
WHO · ECDC · NCDC საქართველო 2025
💊
დანამატების შემოწმება
supplement.ge — 2,095 ინგრედიენტი
ℹ️ეს სისტემა ახდენს ტრიაჟს — არა დიაგნოზს. ყოველი გადაწყვეტილება დაფუძნებულია WHO, AHA, NICE, BTS სახელმძღვანელოებზე. ექიმის კონსულტაცია სავალდებულოა.
პირადი ინფორმაცია
სიმპტომების ზუსტი შეფასებისთვის შეიყვანეთ ასაკი და სქესი
👤სავალდებულო
📏 ანთროპომეტრია
სიმაღლე · წონა · BMI — არასავალდებულო
🩺 სასიცოცხლო მაჩვენებლები
წნევა · პულსი · ტემპერატურა · SpO2 — არასავალდებულო
ნორმა: 90–129
ნორმა: 60–100
36–37.2
12–20
≥95%
სიმპტომების შეფასება
აირჩიეთ სცენარი სისტემის მიხედვით
🔍
კითხვა 1 / 1
📋 მტკიცებულებითი საფუძველი
World Health Organization (WHO) — IMAI სახელმძღვანელო
American Heart Association (AHA) / ACC
National Institute for Health and Care Excellence (NICE)
ICD-11 (2025) · World Health Organization
ეს ინსტრუმენტი ახდენს ტრიაჟს — არა დიაგნოზს. სიმპტომები შეიძლება მიუთითებდეს — ეს არ ნიშნავს, რომ დაავადება გაქვთ. ექიმის კონსულტაცია სავალდებულოა.
📰 სიახლეები ყველა ›
ვაქცინაციის კალენდარი
აირჩიეთ ასაკობრივი ჯგუფი
WHO ECDC NCDC 2025
📚წყარო: NCDC საქართველო 17.09.2025 · WHO · ECDC
ასაკობრივი ჯგუფი
📚წყარო: NCDC საქართველო 17.09.2025 · WHO · ECDC
📰 ვაქცინაციის სიახლეები ყველა ›
დანამატების შემოწმება
გადადით supplement.ge-ზე და შეამოწმეთ ნებისმიერი პროდუქტი
SUPPLEMENT.GE
საქართველოს სასურსათო დანამატების უსაფრთხოების შემოწმების სისტემა
📊 2,095 ინგრედიენტი 📦 688 პროდუქტი
supplement.ge-ზე გადასვლა
ახალი ფანჯარა გაიხსნება
რას შეგიძლიათ შეამოწმოთ
🔬
ინგრედიენტის შემოწმება
NIH · EU · FDA · Health Canada მონაცემები
📷
ეტიკეტის სკანირება
AI ამოიცნობს ყველა ინგრედიენტს ფოტოდან
🌍
ქვეყნის მიხედვით სტატუსი
რეგულაცია 14 ქვეყანაში — აშშ, ევროკავშირი, კანადა
⚠️
წამალთან ინტერაქცია
აუცილებელი გაფრთხილებები მიმდინარე მკურნალობისას
✅ supplement.ge — საქართველოში ერთადერთი სრული სისტემა დანამატების უსაფრთხოების შესაფასებლად, PHIG-ის (საზოგადოებრივი ჯანდაცვის ინსტიტუტის) კონტროლით.